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Past
Patients with peritoneal metastases present unique challenges in diagnosis, 
treatment, predicting future disease behavior. Imaging of peritoneal metastases 
typically underestimates the disease burden.1 Surgical treatment, often with 
complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy 
(CRS/HIPEC), can have high morbidity and is most effective in a carefully selected 
group of patients. Prognosis varies greatly not only by histology, but also by many 
additional unknown factors. The detection of molecular alterations in tumor tissue 
via next generation sequencing (NGS) has led to a revolution in the understanding 
of tumor biology, use of targeted therapies, and assessing response to therapy. 
Cell-free circulating tumor DNA (ctDNA) shed from tumor is measurable in plasma 
using modern NGS techniques and has potential to aid in assessments of disease 
burden and risk of recurrence, in addition to identifying actionable alterations.2 We 
sought to assess the detection and utility of ctDNA in patients with peritoneal 
metastases undergoing surgical resection. 
Present
We found that ctDNA is detectable in patients with peritoneal metastases prior to 
surgical resection, including in 27% of patients with low-grade mucinous 
appendiceal tumors.3 The most common detectable alterations were in TP53 and 
KRAS. A subset of our cohort also underwent tissue-based molecular profiling, and 
these results were 97% concordant with the ctDNA alterations. Finally, we found 
that high levels of ctDNA (regardless of the alteration detected) correlated with 
worse progression-free survival than those with low levels, controlling for grade of 
disease and extent of surgical resection. These findings collectively suggest that 
ctDNA may be a useful tool for disease prognostication in patients with peritoneal 
metastases.
Future
Our results are preliminary and need to be validated in a larger group of patients. In
addition, we are currently further exploring use of ctDNA in this population. Namely,
we are analyzing whether changes in postoperative ctDNA from preoperative results
can further predict oncologic outcomes. We are also attempting to determine 
whether longitudinal assessments could be used for surveillance after surgery. 
Hopefully, this test will prove useful in assessing, surveying, and predicting 
outcomes in this challenging population.
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